The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires treatment with enzyme replacement therapy (ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currently approved FDA products and/or b) are not able or willing to participate in any of the on-going clinical trials in the United States.
Drug: Pegunigalsidase Alfa
Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
Inclusion Criteria:
- In the opinion of the Treating Physician, the patient cannot be adequately treated
with any FDA approved drugs for Fabry and is not able to enroll in any current
clinical trial for Fabry disease.
- Patient (or legal guardian) is able to sign an informed consent prior to treatment.
- A documented diagnosis of Fabry disease.
- Preferably two, but at minimum 1, historical serum creatinine evaluations in the last
2 years with the latest value within the last 6 months.
- Female patients and male patients whose co-partners are of child-bearing potential
agree to use a medically acceptable method of contraception, not including the rhythm
method. Acceptable methods of contraception include hormonal products, intrauterine
device, or male or female condoms. Contraception should be used for 90 days after
treatment discontinuation.
Exclusion Criteria:
- Patients enrolled and currently treated in Study PB-102-F20, and patients enrolled and
currently treated in Extension Study PB-102-F60
- Patients who currently are on treatment under any other ongoing clinical trials of
PRX-102
- History of Type 1 (anaphylaxis or anaphylactoid like) life-threatening
hypersensitivity during previous exposure to other ERTs which could not be handled
with medication
- Women who are breastfeeding may not participate unless they agree to stop
breastfeeding.
- Women who are currently pregnant.
University of Alabama-Birmingham
Birmingham, Alabama, United States
Phoenix Children's Hospital, Inc.
Phoenix, Arizona, United States
University of California Irvine
Orange, California, United States
Central Coas Nephrology
Salinas, California, United States
University of Florida, Division of Pediatric Genetics
Jacksonville, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
University of Iowa
Iowa City, Iowa, United States
Infusion Associates
Grand Rapids, Michigan, United States
Dallas Nephrology Associates
Dallas, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC)
Fairfax, Virginia, United States
Medical Information Chiesi
(888) 661-9260
us.medical@chiesi.com